|
Mutation Information
|
Mutation Site
|
M46L |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
PR |
|
Genotype/Subtype
|
B;C;BF;AE |
|
Viral Reference
|
K03455.1
|
|
Country
|
UK;Germany;Spain;France;Belgium;Greece;South Africa;Uganda;Brazil;Argentina;Peru;USA;Thailand;India;Australia. |
Literature Information
|
PubMed PMID
|
33369017
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2021 |
|
Journal
|
HIV medicine |
|
Title
|
Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study. |
|
Author
|
Baxter JD,Dunn D,Tostevin A,Marvig RL,Bennedbaek M,Cozzi-Lepri A,Sharma S,Kozal MJ,Gompels M,Pinto AN,Lundgren J,INSIGHT START Study Group. |
|
Evidence
|
Using the 2% detection threshold, individual DRMs with the highest prevalence were: PI M46IL (5.5%), RT K103NS (3.5%), RT G190ASE (3.1%), T215ISCDVEN (2.5%), RT M41L (2.2%), RT K219QENR (1.7%) and PI D30N (1.6%).
|
|
|
HIV Mutation Detail Information